Matt Scholz is a co-founder of Oisin Biotechnologies, a longevity startup that is developing a proteome-lipid nanoparticle gene therapy platform. Their lead program is a senolytic gene therapy to target senescent cells.
Matt Scholz is a co-founder of Oisin Biotechnologies, a longevity startup that is developing a proteome-lipid nanoparticle gene therapy platform. Their lead program is a senolytic gene therapy to target senescent cells.